This is a working overview of reverse-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-23. Anything still debated is marked as such rather than presented as settled.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
The M242 is standard equipment on the U. S. Army M2 and M3 Bradley fighting vehicles; it is also in use on the LAV-25. Before the project was cancelled, the Mk44 Bushmaster II 30 mm chain gun (a successor to the M242) was used on the Marine Corps' Expeditionary Fighting Vehicle (EFV). The M242 is also a popular choice of primary armament for armored fighting vehicles manufactured around the world, such as Singapore's Bionix AFVs and as the Rafael Overhead Weapon Station-25 mounted on upgraded M113A2 Ultra IFVs.
=== Prostate cancer === The stroma of the prostate is characteristically muscular. Due to this muscularity, detecting the myofibroblastic phenotypic change indicative of reactive stroma is difficult in an examination of patient pathologic slides. A diagnosis of reactive stroma associated with prostate cancer is one of poor prognosis.
Abbott expanded the range of stores offering EAS products from niche stores such as GNC to mainstream stores such as Walmart and Target. In March 2011, Abbott laboratories removed the EAS brand from international markets and ceased European production of EAS products. This included the closing of the Canadian and UK country businesses and regional distribution in Europe, Australia, and New Zealand along. In August 2018, the brand was discontinued by Abbott Laboratories.
=== Winning streak === Next, Pudzian faced former bodybuilder Erko Jun on 9 November 2019 at KSW 51: Croatia. He won the bout via second round TKO. Pudzianowski was then scheduled to headline KSW 53 against Quentin Domingos on 21 March 2020 before the bout was scrapped due to Pudzianowski's injury. Pudzianowski was set to return after a fifteen month layoff against the undefeated Senegalese heavyweight Serigne Ousmane at KSW 59: Fight Code on 20 March 2021. However, on the day of the fight, Ousmane Dia suffered an acute appendicitis attack and had to be hospitalized. Stepping in on just a few hours notice was Serbia's Nikola Milanovic. Pudzianowski won the bout via TKO in the first round. Pudzianowski faced KSW 1 tournament winner Łukasz Jurkowski on 5 June 2021 at KSW 63: Crime of The Century. Pudzianowski won the fight via TKO in the 3rd round. The fight with Serigne Ousmane Dia was then rebooked and took place at KSW 64: Przybysz vs. Santos on 23 October 2021. Pudzianowski won the fight via knockout 18 seconds into round one. Pudzianowski faced former KSW Middleweight champion Michał Materla at KSW 70: Pudzianowski vs. Materla on 28 May 2022. He won the bout in the first round, knocking out Materla with an uppercut. He was awarded the Knockout of the Night bonus with the win. Pudzianowski faced former two-division champion Mamed Khalidov at KSW 77: Khalidov vs. Pudzianowski on 17 December 2022. Pudzian's 6-win streak was ended after he tapped to ground and pound in the first round.
Myxedema's characteristic physical sign is non-pitting edema, in contrast to pitting edema. Myxedema can also occur in the lower leg (pretibial myxedema) and behind the eyes (exophthalmos). Severe cases, requiring hospitalization can exhibit signs of hypothermia, hypoglycemia, hypotension, respiratory depression, and coma.
Sources: en.wikipedia.org
Whey is left over when milk is coagulated during the process of cheese production. Coagulation can happen by adding acid or rennet. It is a 5% solution of lactose in water and contains the water-soluble proteins of milk as well as some lipid content. Processing can be done by simple drying, or the relative protein content can be increased by removing the lactose, lipids and other non-protein materials. The main method to extract protein from whey is membrane filtration. A variety of membrane pore sizes can be used to selectively let different components of whey go through or be retained. Whey can be passed through "microfiltration" which blocks bacteria, casein micelles, and fat, then passed through "ultrafiltration" (UF) which blocks proteins. The part that does not go through UF is spray-dried into a concentrated whey protein. There are also other ways to concentrate protein using filtration membranes. Ion exchange chromatography is another major method for whey protein extraction. Methods in development include aqueous two-phase extraction and magnetic separation.
3 April The U.S. Department of Defense announced that the death toll for American soldiers in the war had exceeded the 32,629 who had died in the Korean War, based on 312 additional deaths during the week from March 22 to March 28 to bring the toll to 33,641. Laird announced that the U.S. sought to "Vietnamize" the war as quickly as possible but that troop withdrawals would not take place while the PAVN/VC was conducting attacks.
Five hundred members of the public were advised to decontaminate their possessions to prevent possible long-term exposure, and 180 members of the military and 18 vehicles were deployed to assist with decontamination at locations in and around Salisbury. Up to 38 people in Salisbury have been affected by the agent to an undetermined extent. Daniel Gerstein, a former senior official at the U.S. Department of Homeland Security, said it was possible that Novichok nerve agents had been used before in Britain to assassinate Kremlin targets, but had not been detected: "It's entirely likely that we have seen someone expire from this and not realised it. We realised in this case because they were found unresponsive on a park bench. Had it been a higher dose, maybe they would have died and we would have thought it was natural causes." On 20 March 2018, Ahmet Üzümcü, Director-General of the OPCW, said that it would take "another two to three weeks to finalise the analysis" of samples taken from the poisoning of Skripal. On 3 April 2018, the Defence Science and Technology Laboratory announced that it was "completely confident" that the agent used was Novichok, although they still did not know the "precise source" of the agent.
, the first step is to linearise around the disease-free equilibrium (DFE), but for the infected subsystem of non-linear ODEs which describe the production of new infections and changes in state among infected individuals. Epidemiologically, the linearisation reflects that
== History == Prior to the UGR's implementation, the U.S. military had several different types of rations used to feed service members in the rear or out of combat. Among them were the A-ration, consisting of fresh, refrigerated, or frozen food prepared in a kitchen and served in a mess, dining facility, or elsewhere; the B-ration, consisting of packaged, preserved foods prepared in a field kitchen; and the T-ration, a semi-perishable meal packaged, heated, and served in a tray pack similar to frozen meals; among others. This created issues for military cooks, who "had to order an average of 34 separate items for each meal, and could only hope that they arrived when needed", forcing them to manage logistics and administrative functions instead of solely food preparation. Around 1995, the U.S. military launched a modernization program to resolve this issue while also increasing the quality and decreasing the cost of existing rations. Research was headed by the U.S. Army Natick Soldier Research, Development and Engineering Center and the U.S. Army Quartermaster Center and School. In 1999, the UGR was created to simplify logistics and ensure all necessary ingredients were provided, combining elements and offerings of the A-ration, B-ration, T-ration, and commercial items. The UGR was initially trialed with the Army, with their first shipments received around 2000; the Air Force, Marine Corps, and Navy also began receiving UGRs at unspecified dates. The UGR-E was introduced in 2006. The UGR-B was phased out and replaced by the mostly similar UGR-M at an unspecified date.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.